Effects of o-vanillin on K+ transport of red blood cells from patients with sickle cell disease

Blood Cells, Molecules, and Diseases

Volumn 53, Issue 1-2, 2014, Pages 21-26

  Hannemann, A ^a   Cytlak, U M C ^a   Gbotosho, O T ^a   Rees, D C ^b   Tewari, S ^b   Gibson, J S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aromatic aldehydes; O Vanillin; Potassium permeability; Red blood cells; Sickle

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; CALCIUM IONOPHORE; HEMOGLOBIN S; N ETHYLMALEIMIDE; POTASSIUM CHLORIDE COTRANSPORTER; VANILLIN; 2-VANILLIN; BENZALDEHYDE DERIVATIVE; CALCIMYCIN; COTRANSPORTER; POTASSIUM; POTASSIUM-CHLORIDE SYMPORTERS; SODIUM POTASSIUM CHLORIDE COTRANSPORTER;

ARTICLE; CELL ACTIVITY; CELL MEMBRANE PERMEABILITY; CELL VOLUME; CONTROLLED STUDY; DEOXYGENATION; ERYTHROCYTE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; POLYMERIZATION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; CELL SIZE; DRUG EFFECTS; GENETICS; HOMOZYGOTE; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANEMIA, SICKLE CELL; BENZALDEHYDES; BIOLOGICAL TRANSPORT; CALCIMYCIN; CELL MEMBRANE PERMEABILITY; CELL SIZE; ERYTHROCYTES; HEMOGLOBIN, SICKLE; HOMOZYGOTE; HUMANS; POTASSIUM; SODIUM-POTASSIUM-CHLORIDE SYMPORTERS; SYMPORTERS;

EID: 84900002774     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.02.004     Document Type: Article

References (40)

1. Steinberg M.H. Management of sickle cell disease. N. Engl. J. Med. 1999, 340:1021-1030.
2. Nagel R.L., Platt O.S. General pathophysiology of sickle cell anemia. Disorders of Hemoglobin 2001, 494-526. Cambridge University Press, Cambridge. M.H. Steinberg (Ed.).
3. Rees D.C., Williams T.N., Gladwin M.T. Sickle-cell disease. Lancet 2010, 376:2018-2031.
4. Perutz M.F., Mitchison J.M. The state of haemoglobin in sickle-cell anaemia. Nature 1950, 166:677-679.
5. Bunn H.F., Forget B.G. Hemoglobin: Molecular, Genetic and Clinical Aspects 1986, Saunders, Philadelphia.
6. Charache S., et al. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987, 69:109-116.
7. Charache S., et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992, 79:2555-2565.
8. Platt O.S. Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 2008, 358:1362-1369.
9. Zaugg R.H., Walder J.A., Klotz I.M. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. J. Biol. Chem. 1977, 252:8542-8548.
10. Abraham D.J., et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991, 77:1334-1341.
11. Abdulmalik O., et al. 5-Hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br. J. Haematol. 2005, 128:552-561.
12. Acquaye C.T.A., et al. Mode of transport and possible mechanism of action of L-phenylalanine benzyl ester as an anti-sickling agent. Biochim. Biophys. Acta 1982, 693:407-416.
13. Joiner C.H. Cation transport and volume regulation in sickle red blood cells. Am. J. Physiol. 1993, 264:C251-C270.
14. Gibson J.S., Ellory J.C. Membrane transport in sickle cell disease. Blood Cells Mol. Dis. 2002, 28:1-12.
15. Lew V.L., Bookchin R.M. Ion transport pathology in the mechanism of sickle cell dehydration. Physiol. Rev. 2005, 85:179-200.
16. Joiner C.H., Dew A., Ge D.L. Deoxygenation-induced fluxes in sickle cells. I. Relationship between net potassium efflux and net sodium influx. Blood Cells 1988, 13:339-348.
17. 2+ permeability in deoxygenated sickle cells. Blood 1990, 75:2453-2458.
18. 2+ levels of sickle cell anemia red cells. J. Clin. Investig. 1993, 92:2489-2498.
19. Ortiz O.E., Lew V.L., Bookchin R.M. Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells. J. Physiol. 1990, 427:211-226.
20. 2+ and pH in human sickle cells using 31P NMR spectroscopy. J. Biol. Chem. 2002, 277:49911-49920.
21. Speake P.F., Roberts C.A., Gibson J.S. The effect of changes in respiratory blood parameters on the equine red blood cell K-Cl cotransporter. Am. J. Physiol. 1997, 273:C1811-C1818.
22. Dunham P.B., Ellory J.C. Passive potassium transport in low potassium sheep red cells: dependence upon cell volume and chloride. J. Physiol. 1981, 318:511-530.
23. Hannemann A., et al. The use of radioisotopes to characterise the abnormal permeability of red blood cells from sickle cell patients. Radioisotopes: applications in bio-medical science 2011, 151-172. InTech, Rijeka. N. Singh (Ed.).
24. 2+ entry pathway involved in deoxygenation-induced phosphatidylserine exposure in red blood cells from patients with sickle cell disease. Pflugers Arch. - Eur. J. Physiol. 2013, 465:1651-1600.
25. Borgese F., Motais R., Garcia-Romeu F. Regulation of Cl-dependent K transport by oxy-deoxyhemoglobin transitions in trout red cells. Biochim. Biophys. Acta 1991, 1066:252-256.
26. Cossins A.R., et al. Role of protein phosphorylation in control of K flux pathways of trout red blood cells. Am. J. Physiol. 1994, 267:C1641-C1650.
27. - cotransport in vertebrate red cells. Red Cell Membrane Transport in Health and Disease 2003, 197-220. Springer Verlag, Berlin. I. Bernhardt, J.C. Ellory (Eds.).
28. Pressman B.C. Biological applications of ionophores. Annu. Rev. Biochem. 1976, 45:501-530.
29. - cotransport in normal and sickle human red cells. Cell. Physiol. Biochem. 2006, 17:121-128.
30. Beddell C.R., Kneen G., White R.D. The anti-sickling activity of a series of aromatic aldehydes. Br. J. Pharmacol. 1979, 66:70P.
31. Zhang C., et al. Anti-sickling effects of MX-1520, a prodrug of vanillin: an in vivo study using rodents. Br. J. Haematol. 2004, 125:788-795.
32. Kneen G., White R.D. BW12C: a new anti-sickling agent. Br. J. Pharmacol. 1981, 74:965-970.
33. Kenny M.W., Stuart J. Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation. Br. J. Haematol. 1983, 55:465-471.
34. Beddell C.R., et al. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br. J. Pharmacol. 1984, 82:397-407.
35. Stone P.C.W., Nash G.B., Stuart J. Substituted benzaldehydes (12C79 and 589C80) that stabilize oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration. Br. J. Haematol. 1992, 81:419-423.
36. Stuart J., et al. Additive in vitro effects of anti-sickling drugs. Br. J. Haematol. 1994, 86:820-823.
37. Fitzharris P., et al. The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. Br. J. Clin. Pharmacol. 1985, 19:471-481.
38. Keidan A.J., et al. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet 1986, 327:831-834.
39. Arya R., et al. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br. J. Haematol. 1996, 93:817-821.
40. Safo M.K., et al. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds. J. Med. Chem. 2004, 47:4665-4676.